Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin
delivery and diabetes technology company, is supporting the efforts
of Beyond Type 1, a global diabetes advocacy organization, in
fielding its largest marathon team in history, made up of 30
runners with a combined 385 years of experience living with type 1
diabetes. The Beyond Type Run team will be running the TCS New York
City Marathon on November 3, 2019, and Tandem Diabetes Care has
made the t:slim X2™ insulin pump with Basal-IQ® technology
available to all team members. A majority of the team chose to use
the system for their personal diabetes management, training, and
for the marathon.
“At Tandem, we believe in pushing the envelope and achieving
extraordinary things,” says John Sheridan, President and CEO of
Tandem Diabetes Care. “The Beyond Type Run team exemplifies this
spirit, and we are happy to support them with our advanced insulin
delivery technology to help them do their best on race day.”
Keary Cheney, a Beyond Type Run team member, diabetes advocate
and mother of two, has been training with the t:slim X2 insulin
pump with Basal-IQ technology for two months in preparation for the
marathon. She is running for her daughter Zola, who was diagnosed
with diabetes two months after her own diagnosis.
“Ever since the day that type 1 diabetes almost took my life, I
have wanted to do more things that challenge me, that feel
uncomfortable, that cause growth, and that push the limits. At some
point I thought running 26.2 miles would do just that,” said
Cheney. “The t:slim X2 pump with Basal-IQ technology has radically
changed the way I manage my diabetes during workouts and has made
exercising a hundred times easier than when I used injections. Now
I can’t imagine running this race without it.”
Beyond Type Run, co-captained by Rhone CEO and Co-founder Nate
Checketts, and NASCAR driver Ryan Reed, will run through the five
boroughs of New York City to inspire the more than 1.25 million
Americans diagnosed with type 1 diabetes, a chronic, autoimmune
disease.
Learn more about the full Beyond Type Run team at
beyondtype1.org/beyond-type-run.
About Beyond Type 1
Beyond Type 1 (www.beyondtype1.org) is a nonprofit organization
changing what it means to live with diabetes. Through platforms,
programs, resources, and grants, Beyond Type 1 is uniting the
global diabetes community and providing solutions to improve lives
today. Founded in 2015 with a focus on education, advocacy and the
path to a cure for Type 1 diabetes, Beyond Type 1 has grown to also
include programs for those with Type 2 diabetes. A new model of
philanthropy, Beyond Type 1 aims to change what it means to live
with chronic illness.
About the t:slim X2 Insulin Pump with Basal-IQ
Technology
The simple-to-use t:slim X2 insulin pump with Basal-IQ
predictive low glucose suspend technology uses glucose values from
an integrated Dexcom G6 continuous glucose monitor to predict and
help prevent lows with zero fingersticks*. The t:slim X2 insulin
pump includes advanced features like a large color touchscreen,
rechargeable battery, Bluetooth® wireless technology, USB
connectivity and watertight construction (IPX7)1. It is capable of
remote software updates using a personal computer, offering the
potential for in-warranty users to access new features as they meet
necessary regulatory requirements2. The t:slim X2 insulin pump is
up to 38 percent smaller than other insulin pumps and holds up to
300 units of insulin.3
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company dedicated to improving the lives of people with
diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach
to the design, development and commercialization of products for
people with diabetes who use insulin. Tandem’s flagship product,
the t:slim X2 insulin pump, is capable of remote software updates
using a personal computer and features integrated continuous
glucose monitoring. Tandem is based in San Diego, California.
Tandem Diabetes Care and Basal-IQ are registered trademarks, and
t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom and
Dexcom G6 are registered trademarks of Dexcom, Inc. The Bluetooth
wordmark is a registered trademark owned by Bluetooth SIG, Inc. and
any use of such mark by Tandem Diabetes Care, Inc. is under
license. All other third-party marks are the property of their
respective owners.
Important Safety Information for the t:slim X2 Insulin Pump
with Basal-IQ Technology
Federal (USA) law restricts this device to sale by or on the
order of a physician. The t:slim X2 insulin pump with Basal-IQ
technology (the System) consists of the t:slim X2 insulin pump,
which contains Basal-IQ technology, and a compatible CGM. CGM sold
separately. The t:slim X2 insulin pump is intended for the
subcutaneous delivery of insulin, at set and variable rates, for
the management of diabetes mellitus in persons requiring insulin.
The t:slim X2 insulin pump can be used solely for continuous
insulin delivery and as part of the System. When the System is used
with a compatible iCGM, Basal-IQ technology can be used to suspend
insulin delivery based on CGM sensor readings. The System is
indicated for use in individuals 6 years of age and greater. The
System is intended for single patient use and requires a
prescription. The System is indicated for use with
NovoLog/NovoRapid or Humalog U-100 insulin. The System is not
approved for use in pregnant women, persons on dialysis, or
critically ill patients. The pump is not intended for anyone unable
or unwilling to: use the insulin pump, CGM, and all other system
components in accordance with their respective instructions for
use; test blood glucose levels as recommended by their healthcare
provider; demonstrate adequate carb-counting skills; maintain
sufficient diabetes self-care skills; see their healthcare provider
regularly. The user must also have adequate vision and/or hearing
to recognize all functions of the pump, including alerts. For
detailed indications for use and safety information, visit
tandemdiabetes.com/safetyinfo.
* If glucose alerts and CGM readings do not match symptoms or
expectations, use a blood glucose meter to make diabetes treatment
decisions. Dexcom G6 CGM sold separately.
1 Tested to a depth of 3 feet for 30 minutes
2 Additional feature updates are not currently available for the
t:slim X2 insulin pump with Basal-IQ technology and are subject to
future FDA approvals. A prescription and additional training may be
required to access certain future software updates.
3 38 percent smaller than MiniMed 630G and 670G and at least 28
percent smaller than MiniMed 530G, Animas Vibe and Omnipod System.
Data on file, Tandem Diabetes Care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191101005580/en/
Tandem Diabetes Care Contact Information: Media: Steve
Sabicer, 714-907-6264, ssabicer@thesabicergroup.com Investors:
Susan Morrison, 858-366-6900 x7005, IR@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Sep 2023 to Sep 2024